Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma

被引:73
作者
Bihl, Florian
Mosam, Anisa
Henry, Leah N.
Chisholm, John V., III
Dollard, Sheila
Gumbi, Pamela
Cassol, Edana
Page, Taryn
Mueller, Nicolas
Kiepiela, Photini
Martin, Jeff N.
Coovadia, Hoosen A.
Scadden, David T.
Brander, Christian
机构
[1] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Ctr,Ctr Regenerat Med & Technol, Boston, MA USA
[3] Univ KwaZulu Natal, Dept Dermatol, Durban, South Africa
[4] Univ KwaZulu Natal, HIV Pathogenesis Program, Doris Duke Med Res Inst, Durban, South Africa
[5] Univ KwaZulu Natal, Dept Virol, Durban, South Africa
[6] Univ KwaZulu Natal, Fac Hlth Sci, Nelson R Mandela Sch Med, Ctr HIV AIDS Res, Durban, South Africa
[7] Ctr Dis Control & Prevent, Atlanta, GA USA
[8] Ist Sci San Raffaele, AIDS Immunopathogenesis Unit DIBIT, I-20132 Milan, Italy
[9] Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland
[10] Univ Pretoria, HIV1 Immune Pathogenesis & Therapeut Res Program, ZA-0002 Pretoria, South Africa
[11] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA
[12] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA
[13] Harvard Univ, Stem Cell Inst, Boston, MA 02115 USA
关键词
chemotherapy; cytotoxic T lymphocytes; Kaposi's sarcoma; Kaposi's sarcoma-associated herpesvirus; viral immune control; viral load; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; SUB-SAHARAN AFRICA; HUMAN-HERPESVIRUS-8; DNA; PERIPHERAL-BLOOD; TYPE-1; INFECTION; HLA-B; AIDS; RESPONSES; VIREMIA;
D O I
10.1097/QAD.0b013e328182df03
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Kaposi's sarcoma-associated herpesvirus (KSHV) is endemic in South Africa and the clinical manifestation of AIDS-associated Kaposi's sarcoma (KS) represents a significant clinical problem. Whereas the positive effects of HAART on the regression of KS have been well established, less is known about the role of herpesvirus-specific cellular immunity in disease improvement. Design: Thirty-three treatment-naive HIV clade C-infected individuals with KS were randomly assigned into two treatment arms (HAART plus systemic chemotherapy versus HAART alone). KSHV-specific cellular immune responses, viral loads and clinical outcome were evaluated. Methods: KSHV, Epstein-Barr virus and HIV-specific cellular immunity was measured using an IFN-gamma enzyme-linked immunospot assay in samples obtained at baseline and up to 11 months after treatment initiation. Cell-associated KSHV viremia was determined by real-time polymerase chain reaction. Results: Robust increases in CD4 cell counts and suppressed HIV viral loads were seen in parallel with significant increases in the KSHV-specific cellular immune responses over time. Although slowly increasing after 5 months, KSHV-specific T-cell responses were significantly elevated only after I I months, with both lytic and latent antigens being more frequently targeted. A trend towards better clinical outcome with HAART plus chemotherapy treatment was observed compared with HAART alone, and was accompanied by a significant reduction in cellular KSHV viral load in the HAART plus chemotherapy-treated subjects but not those treated with HAART alone after 11 months of treatment. Conclusion: The data show a temporal association between the clinical improvement of KS and the re-appearance of KSHV-specific cellular immunity, and demonstrate an effective suppression of KSHV viral replication using combination therapy.(C)V 2007 Lippincott Williams & Wilkins.
引用
收藏
页码:1245 / 1252
页数:8
相关论文
共 38 条
[1]   Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa [J].
Ablashi, D ;
Chatlynne, L ;
Cooper, H ;
Thomas, D ;
Yadav, M ;
Norhanom, AW ;
Chandana, AK ;
Churdboonchart, V ;
Kulpradist, SAR ;
Patnaik, M ;
Liegmann, K ;
Masood, R ;
Reitz, M ;
Cleghorn, F ;
Manns, A ;
Levine, PH ;
Rabkin, C ;
Biggar, R ;
Jensen, F ;
Gill, P ;
Jack, N ;
Edwards, J ;
Whitman, J ;
Boshoff, C .
BRITISH JOURNAL OF CANCER, 1999, 81 (05) :893-897
[2]  
Bihl FK, 2005, J TRANSL MED, V3
[3]   Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses [J].
Bihl, Florian ;
Frahm, Nicole ;
Di Giammarino, Loriana ;
Sidney, John ;
John, Mina ;
Yusim, Karina ;
Woodberry, Tonia ;
Sango, Kaori ;
Hewitt, Hannah S. ;
Henry, Leah ;
Linde, Caitlyn H. ;
Chisholm, John V., III ;
Zaman, Tauheed M. ;
Pae, Eunice ;
Mallal, Simon ;
Walker, Bruce D. ;
Sette, Alessandro ;
Korber, Bette T. ;
Heckerman, David ;
Brander, Christian .
JOURNAL OF IMMUNOLOGY, 2006, 176 (07) :4094-4101
[4]   The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy [J].
Binley, JM ;
Schiller, DS ;
Ortiz, GM ;
Hurley, A ;
Nixon, DF ;
Markowitz, MM ;
Moore, JP .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04) :1249-1263
[5]   Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS - Patients on highly active antiretroviral therapy [J].
Boivin, G ;
Gaudreau, A ;
Routy, JP .
AIDS, 2000, 14 (13) :1907-1910
[6]   Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia [J].
Bourboulia, D ;
Aldam, D ;
Lagos, D ;
Allen, E ;
Williams, I ;
Cornforth, D ;
Copas, A ;
Boshoff, C .
AIDS, 2004, 18 (03) :485-493
[7]   Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma [J].
Brander, C ;
Raje, N ;
O'Connor, PG ;
Davies, F ;
Davis, J ;
Chauhan, D ;
Hideshima, T ;
Martin, J ;
Osmond, D ;
Kedes, DH ;
Walker, BD ;
Scadden, DT ;
Anderson, KC .
BLOOD, 2002, 100 (02) :698-700
[8]   Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage [J].
Campbell, TB ;
Borok, M ;
Gwanzura, L ;
MaWhinney, S ;
White, IE ;
Ndemera, B ;
Gudza, I ;
Fitzpatrick, L ;
Schooley, RT .
AIDS, 2000, 14 (14) :2109-2116
[9]   Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy [J].
Casazza, JP ;
Betts, MR ;
Picker, LJ ;
Koup, RA .
JOURNAL OF VIROLOGY, 2001, 75 (14) :6508-6516
[10]   Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV) [J].
Chatlynne, LG ;
Ablashi, DV .
SEMINARS IN CANCER BIOLOGY, 1999, 9 (03) :175-185